Last reviewed · How we verify
Acetaminophen (Ofirmev)
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Used for Management of mild to moderate pain, Management of moderate to severe pain with adjunctive opioid therapy, Fever reduction.
At a glance
| Generic name | Acetaminophen (Ofirmev) |
|---|---|
| Also known as | Ofirmev |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes (central nervous system) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen is believed to work primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering the pain threshold and resetting the hypothalamic thermostat. The exact mechanism remains incompletely understood, but it does not significantly inhibit peripheral COX enzymes like NSAIDs do. Ofirmev is the intravenous formulation of acetaminophen, providing rapid systemic delivery for acute pain and fever management.
Approved indications
- Management of mild to moderate pain
- Management of moderate to severe pain with adjunctive opioid therapy
- Fever reduction
Common side effects
- Hepatotoxicity (at high doses or chronic use)
- Nausea
- Vomiting
- Infusion site pain or phlebitis
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetaminophen (Ofirmev) CI brief — competitive landscape report
- Acetaminophen (Ofirmev) updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI